UK markets closed

Agios Pharmaceuticals, Inc. (0HB0.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
33.48+0.45 (+1.36%)
At close: 06:09PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.86
52-week change 336.32%
S&P500 52-week change 323.10%
52-week high 335.35
52-week low 320.13
50-day moving average 326.18
200-day moving average 324.83

Share statistics

Avg vol (3-month) 3522
Avg vol (10-day) 3238
Shares outstanding 558.18M
Implied shares outstanding 6N/A
Float 847.69M
% held by insiders 11.46%
% held by institutions 1107.42%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,496.23%

Management effectiveness

Return on assets (ttm)-22.49%
Return on equity (ttm)-36.83%

Income statement

Revenue (ttm)26.82M
Revenue per share (ttm)0.48
Quarterly revenue growth (yoy)64.80%
Gross profit (ttm)N/A
EBITDA -384.86M
Net income avi to common (ttm)-352.09M
Diluted EPS (ttm)-6.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)776.93M
Total cash per share (mrq)13.83
Total debt (mrq)72M
Total debt/equity (mrq)8.88%
Current ratio (mrq)12.27
Book value per share (mrq)14.50

Cash flow statement

Operating cash flow (ttm)-296.06M
Levered free cash flow (ttm)-215.06M